{"id":"NCT02271854","sponsor":"Novartis","briefTitle":"A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness","officialTitle":"A Randomized, Double-blind, Placebo-controlled, Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel (DSG) 1% Applied Four Times Daily in Subjects Experiencing Acute Delayed Onset Muscle Soreness (DOMS) of the Lower Limbs","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2014-10-22","resultsPosted":"2016-04-05","lastUpdate":"2016-04-05"},"enrollment":102,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Muscle Soreness"],"interventions":[{"type":"DRUG","name":"Diclofenac sodium gel 1%","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"diclofenac sodium gel 1%","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the analgesic efficacy of DSG 1% compared to placebo in the reduction of the pain associated with DOMS","primaryOutcome":{"measure":"Sum of Pain Intensity Differences Over 24 Hours After Initiating Treatment (SPID 24), Derived From POW.","timeFrame":"24 hours","effectByArm":[{"arm":"Diclofenac Sodium Gel 1%","deltaMin":50.15,"sd":35.95},{"arm":"Placebo","deltaMin":54.83,"sd":37.04}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":102},"commonTop":[]}}